Replies to post #735914 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Getting enough BCG is really really important for medium to high risk bladder cancer patients. So, it would not be a good thing for a manufacturer to contribute to a shortage.

https://euoncology.europeanurology.com/article/S2588-9311(23)00206-7/abstract

Adequate BCG treatment was associated with improved OS (HR: 0.82, 95% CI: 0.73–0.92), CSS (HR: 0.64, 95% CI: 0.47–0.86), RFS (HR: 0.80, 95% CI: 0.70–0.92), and PFS (HR: 0.52, 95% CI: 0.39–0.68).

Reduced-dose Connaught strain was associated with the worst survival outcomes.

[manibiotech]

Again deflecting
NWBO needs BCG for trials not for commercial treatments . Apparently others are able to use alternatives . I have already provided proof.
But keep apologizing